(Q24245506)

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

Endothelin induced collagen remodeling in experimental pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Safety and tolerability of bosentan in adults with Eisenmenger physiology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Endothelin receptors in cultured adult rat cardiac fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Sitaxsentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021

Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004434.PUB3

7 January 2021